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Abstract: Multidisciplinary techniques, in particular the
combination of theoretical and experimental immunolo-
gy, can address questions about human immunity that
cannot be answered by other means. From the turnover
of virus-infected cells in vivo, to rates of thymic
production and HLA class I epitope prediction, theoretical
techniques provide a unique insight to supplement
experimental approaches. Here we present our opinion,
with examples, of some of the ways in which mathematics
has contributed in our field of interest: the efficiency of
the human CD8+ T cell response to persistent viruses.
This is an ‘‘Editors’ Outlook’’ article for PLoS Computational
Biology
Introduction
We all carry lifelong, persistent viral infections. More than 70%
of adults are infected with Epstein Barr Virus (EBV), 80%–90%
with Cytomegalovirus, and .90% with Varicella Zoster Virus.
Worldwide, 170 million people are infected with Hepatitis C virus
(HCV) and 33 million with Human Immunodeficiency Virus
(HIV-1). CD8+ T cells are thought to play an important role in
controlling these persistent viral infections. CD8+ T cells recognise
viral antigen in the context of HLA class I molecules (Figure 1) and
are thus activated to kill virus-infected cells via perforin/granzyme
secretion or the Fas/FasL pathway and to secrete antiviral
cytokines. Some persistent viruses such as EBV or Herpes Simplex
Virus adopt a strategy of latency to evade the host immune
response. These viruses are characterised by low or intermittent
levels of antigen expression and a corresponding low level of
CD8+ T cell activation. Their mechanism of survival is clear.
However, other viruses such as HIV-1, HCV, and human T cell
leukemia virus (HTLV-1) replicate persistently and induce chronic
activation of the virus-specific CD8+ T cell response. Yet despite
continuous exposure to this CD8+ T cell response, which is often
large (up to 30% of CD8+ T cells can be specific for HIV-1 or
HTLV-1) and typically has immediate effector function ex vivo,
the CD8+ T cell response fails to eradicate these viruses. Why? In
order to understand why the CD8+ T cell response fails and how
we can improve it, we need to be able to measure the impact of the
CD8+ T cell response in vivo, understand what constitutes an
efficient response, and more controversially, tackle the in vivo
relevance of the CD8+ T cell response. We maintain that, for
humans, none of these questions can be answered with experiment
or mathematics alone. Here we review recent interdisciplinary
work to address these questions in the context of persistent viruses
in humans.
Quantification of CD8+ T Cell Efficiency
We define the efficiency of the CD8+ T cell response as the rate
at which infected cells are killed or new infections are prevented;
that is, efficiency measures the antiviral pressure exerted by the
whole virus-specific CD8+ T cell population. Quantifying antiviral
pressure in vivo is impossible without the use of mathematics.
Mathematical modelling of experimental data allows us to
estimate parameters, such as the rate of CD8+ T cell killing, that
are not explicitly measured experimentally but which determine
the data. Two types of experimental data have been used to
quantify CD8+ T cell efficiency in humans in vivo, both in the
context of HIV-1 infection. The first study, by Wick et al. [1],
analysed a clinical procedure in which CD8+ T cells were isolated
from three HIV-1-infected patients, expanded in vitro with HIV-1
peptides, and then reinfused. Wick et al. fitted a model to the
subsequent productively infected cell dynamics and estimated that
HIV-1-specific CD8+ T cells killed productively infected cells at a
median rate of 0.129 ml cell21 day21. There are approximately
50–65 HIV-specific CD8+ T cells per ml of plasma ([2] gives
median CD8 count = 500 cells ml21, average frequency of HIV-1-
specific CD8+ T cells = 10%; i.e., a specific count of 50 specific
CD8 ml21; [3] gives median CD8 count = 860 cells ml21, average
frequency of HIV-1-specific CD8+ T cells = 7.5%; i.e., a specific
count of 65 specific CD8 ml21). So Wick’s estimate is equivalent to
a lytic efficiency of 6.5–8.4 day21. This estimate of CD8+ T cell
killing is an order of magnitude higher than the total death rate
attributable to all causes (including CD8+ T cell killing, activation
induced cell death, and cytopathic effect of HIV-1), which has
been estimated at 0.7–1 day21 [4,5]. The apparent overestimate of
CD8+ T cell killing may be explained by biological factors; for
example, the infused expanded CD8+ T cells could be more
efficient than naturally occurring CD8+ T cells. Alternatively, the
problem may lie in the model assumptions. For instance, it was
assumed that all antiviral effects were exerted via lysis (i.e.,
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reduction in infected cells due to non-lytic factors would have been
attributed to lysis, Box 1), and many of the fixed parameters in the
model were poorly known at the time of the study. Nevertheless,
this represents the first estimate of the lytic potential of human
CD8+ T cells in vivo.
In the second study, the rate of CD8+ T cell killing was
estimated by analysing HIV-1 escape variants [6,7]. Briefly, the
difference in growth rate in vivo between a viral variant which has
escaped the CD8+ T cell response and the wild type reflects the
difference in rate of CD8+ T cell killing of the two strains offset by
any fitness cost incurred by the escape variant. Therefore the rate
of CD8+ T cell killing (attributable to a single response) can be
estimated by quantifying the rate of escape and the fitness cost.
The rate of escape and fitness cost can be quantified by fitting a
simple mathematical model to longitudinal viral sequence data [6].
This work indicated that, in late primary/chronic infection, CD8+
T cell efficiency was unexpectedly low (0.1–0.2 d21), and thus
CD8+ T cell killing was responsible for only 10%–20% of infected
cell death. This estimate is lower than, and therefore compatible
with, the total death rate of productively infected cells of 0.7–
1 d21, but the lack of independent quantitative approaches makes
it difficult to corroborate this estimate. If it is true that CD8+ T
cells are only responsible for a minority of infected cell death, this
would explain the failure to see a decrease in infected cell death
when the CD8+ T cell response is weak such as in individuals with
low CD4+ T cell count [8] or following CD8+ T cell depletion in
simian immunodeficiency virus (SIV)-infected macaques (a model
of HIV-1 infection) [9,10]. Furthermore, a large amount of cell
death that is not attributable to direct CD8+ T cell killing is
consistent with the high death rate of uninfected cells which has
been observed in HIV-1 infection [11,12]. Finally, a low estimate
of CD8+ T cell killing in chronic infection should perhaps not be
totally unexpected as persistent viral infection has been associated
with reduced CD8+ T cell function and exhaustion, particularly in
the context of HIV-1 infection [13–16]. Consistent with this, it was
shown that escape was significantly more rapid in late primary
than in chronic HIV-1 infection [6], an observation that was
confirmed and extended by subsequent work in very early HIV-1
infection [17]. The cause of this difference remains unknown [18].
In the absence of other studies to quantify the efficiency of
human CD8+ T cells in vivo, it is necessary to turn to animal
models, where a wider range of approaches are possible, to
corroborate the estimates in humans. In chronic SIV infection,
estimates of total CD8+ T cell efficiency derived from CD8+
depletion experiments (median 0.3–0.4 d21 [19]) and from
modelling longitudinal data using the approach of Regoes et al.
[20] (median 0.76 d21 [21]) are similar to estimates from
modelling SIV escape in chronic infection (approximately
0.8 d21) [22,23], lending credence to the quantification of
efficiency from viral escape. Interestingly, both in chronic
[6,22,23] and primary infection [6,17,22–25], the rate of CD8+
T cell killing was substantially higher in macaques than in humans
[22]. Suggestions to the contrary [23] failed to take into account
differences in fitness costs between wild type and escape variant
virus. In LCMV-infected mice, the rate of CD8+ T cell killing is
2–3 orders of magnitude higher than in humans or macaques in
Figure 1. CD8+ T cells recognise virally infected cells via their T
cell receptor (TCR). The TCR binds complexes of viral peptides and
HLA class I molecules at the surface of virus-infected cells. Following
CD8+ T cell recognition of the infected cell, the CD8+ T cell effector
mechanisms are triggered. CD8+ effector mechanisms can be lytic
(killing of the infected cell) and/or non-lytic (secretion of cytokines such
as IFNg and TNFa which reduce the probability of cell infection and viral
production).
doi:10.1371/journal.pcbi.1002381.g001
Box 1. Models of Lytic and Non-Lytic CD8+ T
Cell Mechanisms
A model in which CD8+ T cells are assumed to kill infected
cells typically has the following form:
_T~bTV{dT{kET,
where T* is the number of virus-infected cells, V is viral
load, b is the infection rate, T is the number of uninfected
target cells, E is the number of virus-specific CD8+ T cells, k
is the rate of CD8+ T cell killing, and d is the (CD8+ T cell-
independent) death rate of infected cells.
Non-lytic mechanisms can decrease the rate at which
uninfected CD4+ T cells become infected or the rate of
viral production. We have modelled the impact of CD8+ T
cells on the rate of infection [19,21] by describing the
infection rate as a function of the size of the CD8+ T cell
population:
_T~
b
1zgE
TV{dT:
A non-lytic effect of CD8+ T cells on viral production rate
can be described in a similar way [19,21].
Most models of the CD8+ T cell response assume that
CD8+ T cells lyse their targets. If in fact CD8+ T cells act
mainly via non-lytic mechanisms, then this will change the
model conclusions and may explain some of the discrep-
ancies in the literature. For instance, if most CD8+ T cell
control is mediated via non-lytic mechanisms, this may
explain why Wick’s estimates of CD8+ T cell killing are in
excess of the total death rate of infected cells; that is,
control of infected cells may have been misattributed to
killing of infected cells, leading to an overestimate of their
death rate. How non-lytic mechanisms will affect death
rates inferred from HIV-1 escape from CD8+ T cells is
unclear; we are currently investigating this question.
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both acute and chronic infection [26–29]; further studies are
urgently needed to understand whether these differences are
genuine inter-species differences, differences between viruses, or
simply differences in experimental and theoretical techniques. For
an excellent, considerably more comprehensive, review of work to
quantify CD8+ T cell efficiency, see Regoes et al. [30].
Determinants of CD8+ T Cell Efficiency
Identifying the determinants of an efficient CD8+ T cell
response in humans is non-trivial. Measurements of CD8+ T cell
frequency, phenotype, function, and specificity are informative,
but because antigen load influences each of these factors, it can be
difficult to ascertain if a particular immune profile is the cause or
effect of good pathogen control [31–33]. This is exemplified by
one ubiquitous method to determine the strength of the CD8+ T
cell response: measurement of the frequency of virus-specific cells
(by, e.g., tetramer or IFNg ELISpot) with the assumption that a
large response is a strong, efficient one. In a cross-sectional cohort
of HIV-1-infected individuals, a negative correlation between the
frequency of tetramer-positive CD8+ T cells and plasma viral load
was observed; it was concluded from this that CD8+ T cells
controlled HIV-1 viremia [34]. However, theoretical work has
shown that inferring CD8+ T cell control from CD8+ T cell
frequency is problematic because of feedback between viral load
and CD8+ T cell frequency [35,36]; that is, the frequency is both
the cause and effect of the viral load. This concern has been borne
out by subsequent longitudinal studies in which the magnitude of
the HIV-1-specific CD8+ T cell response failed to predict viral
load or survival time [37–39] and elite control of HIV infection
was associated with the lowest breadth and frequency of HIV-
specific CD8+ T cells [40]. We conclude that purely experimental
descriptors of the CD8+ T cell response tell us about the
correlates, but not the determinants, of good pathogen control.
An alternative approach is to focus on host genetic determinants
of CD8+ T cell efficiency (as here the direction of causality is
unequivocal) and use mathematical methods to understand why
certain genes are protective or detrimental. This approach was
applied very effectively by Borghans et al. [41], who found that
HLA class I alleles that are significantly associated with good
control of HIV-1 infection (HLA-B*57:01, B*58:01, and B*27:05)
showed a preference for presenting peptides from the viral Gag
p24 protein when compared with alleles associated with poor
control (B*35:03 and B*53:01). Borghans et al. conclude that Gag-
specific CD8+ T cells are protective. It is therefore surprising that
Vider-Shalit et al. found that over the course of the HIV epidemic,
in contrast to other HIV proteins, Gag is evolving to gain epitopes
[42]. They hypothesised that Gag-specific CD8+ T cell responses
were inefficient and Gag immunogenicity had evolved as a decoy
to reduce the CD8+ T cell response against proteins expressed
early in the viral life cycle which may be more effective targets
[43]. However, this result was not reproduced by Schmid et al.,
who showed that the number of Gag epitopes (in common with all
HIV-1 CD8+ T epitopes) has remained remarkably constant in
the population over time [44]. The two main differences between
the work of Schmid and Vider-Shalit are the choice of epitope
prediction software and the dating applied to the sequences.
Schmid et al. used NetCTL and MHCpathway, which were the
best performing algorithms at the time [45]; the software used by
Vider-Shalit has not been benchmarked. Schmid dated sequences
by time of sampling, and Vider-Shalit inferred dates from levels on
a phylogentic tree. In principal it should be straightforward to
investigate these discrepancies and arrive at a definitive conclu-
sion.
In a related study, MacNamara et al. used HLA class I epitope
prediction software [45–48] to investigate why, in HTLV-1
infection, some individuals remained healthy, asymptomatic
carriers of the virus and others developed the inflammatory
disease HAM/TSP. In a cohort of HTLV-1-infected participants,
they showed that individuals with HLA class I alleles that were
predicted to strongly bind the HTLV-1 protein HBZ had a lower
proviral load and were more likely to be asymptomatic [49]. They
also showed that CD8+ T cell effectiveness is determined by
protein specificity and produced a ranked list of the proteins
targeted by the most protective CD8+ T cell response through to
the least protective CD8+ T cell response: useful information for
vaccine design. They concluded that CD8+ cells specific to HBZ,
not the immunodominant protein Tax, are the most protective.
This challenges the prevailing assumption that the immunodomi-
nant response is the most important.
More generally, Rao et al. have studied the differences between
HLA-A and HLA-B molecules [50]. The HLA-B locus is the most
polymorphic and the most rapidly evolving of the three major
HLA class I loci, and it has also been suggested that CD8+ T cell
responses restricted by HLA-B alleles are more likely to be
protective [51]. Using a bioinformatic approach Rao et al. found
that HLA-B epitopes had significantly weaker binding affinities
than HLA-A epitopes and were less diverse [50]. These
observations ran counter to many people’s assumptions and have
triggered further investigations.
The HLA class I genes are not the only genetic determinants of
CD8+ T cell efficiency that have been subjected to a theoretical
approach. Genes coding for the killer immunoglobulin-like
receptors (KIRs) have also been analysed. KIRs are a family of
receptors that are expressed predominantly on natural killer (NK)
cells but also on a subset of T cells [52,53]. KIRs bind HLA class I
molecules and have both activating and inhibitory forms [54].
KIRs are rapidly evolving, and even amongst primates, only our
nearest relatives possess the same KIR-HLA ligand pairs as us. In
mice, the functional homologue of KIRs are the Ly49 receptors.
These receptors are quite distinct from KIRs in structure and
patterns of expression [55]. Lack of an accurate animal model has
hindered work on the role of KIRs in adaptive immunity, making
a theoretical approach particularly beneficial. Seich al Basatena
et al. tested the hypothesis that KIR background determines the
efficiency of the CD8+ T cell response [56]. They investigated two
chronic viral infections—HCV and HTLV-1—using cohorts of
infected individuals. They selected HLA class I molecules
previously described to be significantly associated with clinical
outcome (HLA-B*57 in HCV [57–59]; C*08, A*02, and B*54 in
HTLV-1 [60,61]), stratified the cohorts by KIR genotype, and
then re-examined the HLA associations in each stratum. They
found that one particular inhibitory KIR gene, namely KIR2DL2,
consistently enhanced HLA class I associations. That is, associations
between outcome and HLA class I alleles were strong when
KIR2DL2was present but weak when KIR2DL2was absent [56]. For
instance, in HCV infection, amongst KIR2DL2-homozygotes,
individuals with HLA-B*57 were 5 times more likely to spontane-
ously clear the virus than individuals without B*57; if they failed to
clear they had a viral load that was reduced by 6.5 logs. In KIR2DL2
heterozygote individuals, B*57 was still protective but the degree of
protection afforded was reduced: individuals with B*57 were now
twice as likely to spontaneously clear the virus; if they failed to clear,
viral load was reduced by 4 logs. In contrast, in KIR2DL2-negative
individuals, B*57 had no significant effect on clearance or viral load.
It appears that B*57, a well-described protective allele, only
efficiently protects if KIR2DL2 is also present. If an additional gene
needs to be present for an HLA class I molecule to be effective, then
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this could explain why the protective or detrimental effects of
particular HLA alleles are not always manifest. Applying this
reasoning to HTLV-1 it was possible to explain two long-standing
paradoxes in the field: why C*08 doesn’t reduce proviral load in
HAM/TSP patients and why B*54 isn’t associated with increased
proviral load in asymptomatic carriers.
Many associations between disease and pairs of KIR-HLA genes
have been reported [62–66]. In each case the KIR-HLA pair
consisted of a KIR with its HLA ligand and the effect was attributed
to direct NK killing. What Seich al Basatena et al. observed is quite
different. They found that associations between HLA class I
molecules and disease outcome are weak in the absence of KIR2DL2
but are enhanced in the presence of KIR2DL2. This is true for
multiple HLA-A, B, and C alleles, most of which do not bind
KIR2DL2. They saw this effect in two different virus infections and
for both protective and detrimental HLA associations. In contrast,
KIR2DL2 with its HLA-C1 ligand (not in the context of protective
or detrimental HLA molecules) has no detectable impact on any
measure for either virus [56]. It is hard to reconcile these
observations with direct NK killing (Figure 2a). Instead they
hypothesised that KIR2DL2, a receptor typically associated with
innate immunity, is enhancing the effectiveness of the CD8+ T cell
response by increasing CD8+ T cell survival (Figure 2b). This is an
example in which theory has suggested new biology: a novel role for
an ‘‘innate’’ receptor in adaptive immunity.
Temporal and spatial factors—for example, how often does a
CD8+ T cell meet infected cells bearing a sufficient density of
cognate antigen—will also impact of the effectiveness of CD8+ T-
cell-mediated control. Mathematical modelling, using cellular
automata [67], cellular Potts models [68], and the multicompart-
ment models, exemplified by the work of Textor et al. [69], is
contributing to the identification of the physical determinants of
CD8+ T cell efficiency, but this work is beyond the scope of the
current review.
Does CD8+ T Cell Efficiency Matter?
One of the hardest, but perhaps the most important, question to
answer is, What is the impact of CD8+ T cell efficiency on clinical
outcome and to what extent do between-individual differences in
clinical outcome and viral load reflect differences in CD8+ T cell
efficiency? The two strongest arguments to suggest that CD8+ T
cells matter in chronic infections of humans are (i) the observation
that certain HLA class I alleles are significantly associated with
clinical outcome and (ii) that genetically variable viruses like HIV-
1 and HCV evolve mutations that allow them to evade the CD8+
T cell response. These observations tell us that CD8+ T cells
matter but, alone, do not tell us how much they matter.
Interdisciplinary studies have taken these observations and used
them to quantify the in vivo relevance of CD8+ T cells.
(i) HLA Associations. Surprisingly, although associations
between particular HLA class I molecules and clinical
outcome are highly significant, the fraction of variation in
outcome that can be explained by HLA alleles is rather small
(Figure 3), though this does increase by a factor of 2–4 in
KIR2DL2+ individuals. Clearly, HLA associations tell us
about differences in HLA molecules, so a small explained
fraction does not necessarily mean CD8+ T cell responses are
unimportant; it could be that all CD8+ T cell responses are
rather similar regardless of their restriction. However, it does
Figure 2. Proposed mechanism to explain inhibitory KIR enhancement of HLA class I associations. KIR-HLA associations are typically
attributed to direct NK action (a). However, Seich al Basatena’s observations do not appear to be compatible with direct NK killing for four reasons.
Firstly, most of the HLA molecules which were enhanced do not bind KIR2DL2. Secondly, both protective and detrimental HLA associations were
enhanced. Thirdly, KIR2DL2 with or without its C1 ligand (i.e., not in the context of a particular protective or detrimental HLA allele) had no effect on
any outcome for HCV or HTLV-1. And finally, the protective effect of binding HBZ was enhanced, and NK cells display some peptide specificity, but
such marked protein specificity is more reminiscent of T cells [56]. Instead they hypothesise that the downstream effectors are CD8+ T cells (b). They
postulate that KIR2DL2 enhances CD8+ T cell responses by increasing the survival of memory CD8+ T cells. Either because (i) inhibitory KIR on CD8+ T
cells are associated with reduced activation induced cell death and protection from exhaustion [77–79] or (ii) inhibitory KIR on NK cells reduce NK-
killing of activated CD8+ T cells [80,81].
doi:10.1371/journal.pcbi.1002381.g002
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caution us that we should not assume that the CD8+ T cell
response is important just because HLA associations are
highly significant. Furthermore, it implies that the majority of
between-individual variation in clinical outcome is unlikely to
be due to differences in HLA class I genotype.
(ii) Viral Escape. Kadolsky et al. used two independent
computational methods to quantify the impact of escape from
CD8+ T cells in chronic HIV-1 infection: simulation of the
emergence of HIV-1 escape variants and statistical analysis of
a cross-sectional cohort [70]. Both methods estimated that
escape at a single epitope increased log viral load by 0.051–
0.11 copies.ml21. The number of escape events accounted for
approximately 6% of the viral load variation in the cohort
[70]. Thus, escape from CD8+ T cells has a measurable,
statistically significant impact on viral load, but the biological
impact is modest. This small increase in viral load may reflect a
high fitness cost of the escape variant virus (though estimates of
fitness cost are typically quite low [6,25]), or it may indicate
that, in chronic HIV-1 infection, the weakened CD8+ T cell
response is exerting poor control. Again this study implies that
differences in CD8+ T cell escape cannot explain the
substantial inter-individual variations in HIV viral load.
Mechanism of Action of CD8+ T Cells
Perhaps the most immediate demonstration of the importance
of CD8+ T cell is the dramatic rise in viral load following their
depletion [71,72]. Klatt et al. [9] and Wong et al. [73] applied the
pioneering mathematical method of Perelson et al. and Nowak
et al. [74,75] to estimate the lifespan of productively infected cells
in CD8+ cell-depleted macaques and control macaques with an
intact CD8+ T cell response. Unexpectedly, they found no
difference in cell lifespan. The authors concluded that CD8+ T
cells don’t play a major role in decreasing the lifespan of
productively infected cells. They proposed instead that CD8+ T
cells control viremia via a non-lytic mechanism.
Elemans et al. [19] extended this study. They found that the
measurements of infected cell lifespan of Klatt et al. and Wong
et al. were not accurate enough to detect the expected increase in
lifespan following depletion, implying that the experimental results
could not exclude the possibility that all CD8+ T cell control was
via lysis. However, on fitting an extensive set of lytic and non-lytic
models to the experimental data (including models from [8,76]),
they found that a non-lytic model in which CD8+ T cells prevent
new cells from becoming infected predicted the data significantly
better than other models [19]. They conclude that the total rate at
which infected cells are killed or new infections are prevented was
0.3–0.4 d21 and that most of this control was via nonlytic
mechanisms. These results are compatible with earlier findings
that most of the death of productively infected cells is CD8+ T-
cell-independent [6,21].
Future Directions
Mathematical modelling of experimental data can provide a
unique angle to help understand human immunity. However,
mathematics continues to raise as many questions as it answers.
Why is CD8+ T cell killing so much more effective in mice than
men? Why does CD8+ T cell efficiency decline in HIV-1 infection,
and how does KIR2DL2 enhance CD8+ T cell efficiency? These
are just some of the questions raised by a quantitative approach
that need to be addressed.
Figure 3. The variation in outcome that can be explained by
individual HLA class I alleles in HIV-1, HTLV-1 and HCV
infections. The explained fraction (EF) was calculated following Nelson
[82]; data for HCV and HTLV-1 were taken from [56], and data for HIV-1
were taken from [40,83]. 95% confidence intervals were estimated by
bootstrapping the data 5,000 times, trimming the 5% extremes, and
then calculating the range in which 95% of the remaining data lay. Due
to linkage between the HLA alleles, the EF is not additive; so for
instance, in HTLV-1 infection, the three alleles HLA-A*02, C*08, and B*54
together only explain 6.6% of the outcome. The outcomes explained
are HCV: spontaneous clearance v persistence; HTLV-1: asymptomatic
carriage v HAM/TSP; HIV-1: elite control v viremic control v progression.
doi:10.1371/journal.pcbi.1002381.g003
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